Evidence map›Paper›PMID 33881621›Full record

ArticleEuropean archives of psychiatry and clinical neuroscience2022

The impact of the COVID-19 pandemic on negative symptoms in individuals at clinical high-risk for psychosis and outpatients with chronic schizophrenia.

Gregory P Strauss, Kelsey I Macdonald, Ivan Ruiz, Ian M Raugh, Lisa A Bartolomeo, Sydney H James

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European archives of psychiatry and clinical neuroscience, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Trial
  4. Review
  5. Article
  6. Article
  7. Effect of the COVID-19 Pandemic on Psychiatric Service Use Among Psychiatric Outpatients.Turk psikiyatri dergisi = Turkish journal of psychiatry · 2025
    Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Gregory P StraussDepartment of Psychology, University of Georgia, 125 Baldwin St., Athens, GA, 30602, USA. gstrauss@uga.edu.
Kelsey I MacdonaldDepartment of Psychology, University of Georgia, 125 Baldwin St., Athens, GA, 30602, USA.
Ivan RuizDepartment of Psychology, University of Georgia, 125 Baldwin St., Athens, GA, 30602, USA.
Ian M RaughDepartment of Psychology, University of Georgia, 125 Baldwin St., Athens, GA, 30602, USA.
Lisa A BartolomeoDepartment of Psychology, University of Georgia, 125 Baldwin St., Athens, GA, 30602, USA.
Sydney H JamesDepartment of Psychology, University of Georgia, 125 Baldwin St., Athens, GA, 30602, USA.

Funding

Prodromal Inventory for Negative Symptoms (PINS): A Development and Validation StudyR01MH116039 · NIMH · UNIVERSITY OF GEORGIA · PI MITTAL, VIJAY A, STRAUSS, GREGORY P · 2019 to 2023
$3.1M
Computationally modeling the failure of effort to become a secondary reinforcer in schizophreniaR21MH122863 · NIMH · UNIVERSITY OF GEORGIA · PI SHENHAV, AMITAI, STRAUSS, GREGORY P · 2020 to 2020
$441k
NIMH NIH HHS R01 MH116039NIMH NIH HHS R01MH116039NIMH NIH HHS R21-MH122863
6 · The paper itself

Abstract

Negative symptoms are core features of schizophrenia-spectrum disorders that are frequently observed across all phases of illness. By their nature, COVID-19 social isolation, physical distancing, and health precautions induce behavioural aspects of negative symptoms. However, it is unclear whether these prevention measures also lead to increases in experiential negative symptoms, whether such effects are equivalent across individual negative symptom domains, and if exacerbations occur equivalently across phases of illness. The current study compared negative symptom severity scores obtained during the pandemic to pre-pandemic assessments in two samples: (1) outpatients with chronic schizophrenia (SZ: n = 32) and matched healthy controls (CN: n = 31) and (2) individuals at clinical high risk for psychosis (CHR: n = 25) and matched CN (n = 30). Pre-pandemic ratings of negative symptoms were clinically elevated in SZ and CHR groups, which did not differ from each other in severity. In SZ, ratings obtained during the pandemic were significantly higher than pre-pandemic ratings for all 5 domains (alogia, blunted affect, anhedonia, avolition, and asociality) and item-level analyses indicated that exacerbations occurred on both experiential and behavioral symptoms of anhedonia, avolition, and asociality. In contrast, CHR only exhibited increases in anhedonia and avolition items during the pandemic compared to pre-ratings. Findings suggest that negative symptoms should be a critical treatment target during and after the pandemic in the schizophrenia spectrum given that they are worsening and critically related to risk for conversion, functional outcome, and recovery.

Indexed as

COVID-19OutpatientsPandemicsPsychotic DisordersSchizophrenic PsychologyAnhedoniaCase-Control StudiesChronic DiseaseHumansRisk AssessmentSchizophreniaAttenuated psychosis syndromeCoronavirusPandemicProdrome

Identifiers

PMID33881621
PMCPMC8057945

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.